Pfizer Pays Back Lilly: Geodon Promotions Focus On Zyprexa Diabetes Risk
Executive Summary
Pfizer is highlighting the incidence of diabetes associated with "some atypical antipsychotics" in its promotions for Geodon (ziprasidone)
You may also be interested in...
Geodon, Abilify Have Low Diabetes Risk, ADA Says; Lilly Disagrees
An American Diabetes Association "consensus" statement on antipsychotics and the risk of diabetes may help Pfizer and Bristol-Myers Squibb make the case to FDA to exempt Geodon and Abilify from class labeling
Geodon, Abilify Have Low Diabetes Risk, ADA Says; Lilly Disagrees
An American Diabetes Association "consensus" statement on antipsychotics and the risk of diabetes may help Pfizer and Bristol-Myers Squibb make the case to FDA to exempt Geodon and Abilify from class labeling
FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk
The comparative risk for diabetes among atypical antipsychotics needs further research, FDA says in a letter to six manufacturers requesting a diabetes and hyperglycemia warning across the class